Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 1, 2024HIV/AIDS - Research and Palliative CareOpen Access

Switching to Dolutegravir/Lamivudine Two-Drug Regimen: Durability and Virologic Outcomes by Age, Sex, and Race in Routine US Clinical Care

View Full Paper
Ask AI
Bookmark
Share

Authors

GPGerald PieroneLBLaurence BrunetJFJennifer S Fusco

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Pierone et al. (2024) studied this question.

synapsesocial.com/papers/68e71030b6db6435876896fbhttps://doi.org/10.2147/hiv.s452130
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical outcomes of switching to dolutegravir/lamivudine dual therapy in people living with HIV: A single‐centre retrospective study2025
  2. 2‘Leaving no stones unturned’: up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch regimen in the ODOACRE cohort2026
  3. 3DTG + 3TC dual therapy for the treatment Naïve patients with viral load exceeding 500,000 copies/mL: a retrospective study2024 · 4 citations
  4. 4ARMED: an Australian cohort retrospective observational study to understand motivations for switching and clinical outcomes of individuals switching to dolutegravir/lamivudine2026
  5. 5Effectiveness and safety of dolutegravir plus lamivudine in treating HIV in China, including outcomes of patients coinfected with tuberculosis2024 · 1 citations